Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness.
about
Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseCardiovascular disease risk amongst African black patients with rheumatoid arthritis: the need for population specific stratificationAngiotensin II in inflammation, immunity and rheumatoid arthritisDifferential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short durationEndothelial dysfunction in chronic inflammatory diseasesEarly vascular alterations in SLE and RA patients--a step towards understanding the associated cardiovascular risk.Cardiovascular disease in rheumatoid arthritis: a systematic literature review in latin america.Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis.Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatmentIncreased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study.The association between functional and morphological assessments of endothelial function in patients with rheumatoid arthritis: a cross-sectional studyRetinol binding protein 4 concentrations relate to enhanced atherosclerosis in obese patients with rheumatoid arthritisSystemic inflammation and early atheroma formation: are they related?Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis.Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids.The increased cardiovascular risk in patients affected by autoimmune diseases: review of the various manifestations.Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis.Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing diseaseMethotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis.Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity.Association of Cardiovascular Risk Factors with Carotid Intima Media Thickness in Patients with Rheumatoid Arthritis with Low Disease Activity Compared to Controls: A Cross-Sectional Study.Endothelial Dysfunction in Rheumatoid Arthritis: Mechanistic Insights and Correlation with Circulating Markers of Systemic Inflammation.Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis.Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis.Contractile, but not endothelial, dysfunction in early inflammatory arthritis: a possible role for matrix metalloproteinase-9High Concentrations of Angiopoietin-Like Protein 4 Detected in Serum from Patients with Rheumatoid Arthritis Can Be Explained by Non-Specific Antibody ReactivitySubclinical cardiovascular system changes in obese patients with juvenile idiopathic arthritisThe role of inflammation, the autonomic nervous system and classical cardiovascular disease risk factors on subendocardial viability ratio in patients with RA: a cross-sectional and longitudinal study.Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.Marked independent relationship between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritisTowards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment.Independent associations of total and high molecular weight adiponectin with cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with rheumatoid arthritis: a cross-sectional study.Unresolved issues in biologic therapy for rheumatoid arthritis.Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?Aortic aneurysm associated with rheumatoid arthritis: a population-based cross-sectional study.Targeting vascular (endothelial) dysfunction.The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis.Prevalence of atherosclerosis in patients with inactive rheumatoid arthritis.Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis.
P2860
Q26801173-530F5C1E-93E7-4DB6-8FA8-478D98C1F303Q26851800-BBAA0E65-C5AF-4AFE-9BE1-A4C5C3C5D8B9Q26991828-535FFBBE-DAA1-4CBA-85AD-E6941F1E99BCQ33593925-D5DB53F2-D6D7-4B34-9863-96C519307EB3Q34072179-8CB08049-6080-4D5F-A67A-95B2CB06542CQ34409903-B9E2942A-09D5-485E-B85D-1CEB7792EB54Q34495257-4DAD9D26-F667-4515-AD62-CEB32DCB0DC5Q34550743-DC055396-7F22-4E3F-93D4-3D0D97A31C4EQ34563216-68170E97-1275-432B-812F-3DACFE2518C0Q34614038-1696B652-36B4-4F4C-B5D6-1ED417D59D1DQ34980274-61716643-4CC8-466D-A1E6-DF44BA6A1100Q35126137-7489B508-D366-42AD-8660-C32F24C56334Q35154761-7397C74D-E21C-4B10-A0C6-F4452D3DCE24Q35257568-60DABE6B-39DD-43A9-A2FE-C8767168B296Q35295398-2A902ECC-5D58-489A-981F-5A5A88ACE03CQ35387131-3B249D79-BD50-4E43-82D3-1118E830FC20Q35489690-75BF67EC-1423-42B0-AB6F-83F65BD97DEEQ35557952-D04DF179-89C5-418A-B108-1B00092F2CBDQ35673987-9B9D69D1-DA8F-4963-AD64-66D01896233FQ35738718-98BC1F5D-36F3-4DD6-87E2-F6C9EDABB108Q35814936-050A6C03-4622-41EB-A53E-3BA2D0647E9EQ35892871-CC066DB5-050B-44A8-9AFD-F200C90834B5Q36167351-556B6A81-BA72-4741-AC80-1957D1963435Q36172927-C6D4DE44-11E4-4873-B376-87FE20BAB1BDQ36246065-CF6A5C88-7DAF-404A-A0EF-5DC036C9BD35Q36253978-83241354-CF5C-4B6A-8A2F-6BE876C0A9F4Q36255319-59E3B780-ABF5-4F16-BF28-BF8F82D8324DQ36716845-06F49919-6F61-4A12-9710-F9AC7FBAAF81Q36907676-CEB535EB-6C22-407A-8775-23517EA47EC4Q37058791-3FA2A75D-BC61-479F-8102-05C4ADB49768Q37433269-6DFC6491-F314-492E-9F6D-6D71B64266E5Q37533298-68C5EB0A-DEB6-4F80-9B2D-837CF686DE2EQ37689920-106D12F4-8B44-45A5-B905-B8A389AF5087Q37851001-1407777F-99BC-40EE-99C8-966C9F1C57E2Q38185646-B5FED26D-3B1E-4FDB-9AE6-A6F5A2F47B97Q38833241-0C30BB0D-6E8B-4514-B6D6-14DB306F8CA8Q38836199-AB0BED78-C918-4313-882D-D79AC621A58BQ39218194-9EAC8366-2A31-404B-A2A6-FCEBB1866AD3Q40784903-1F887106-F689-4B30-B679-1C45E011DA78Q40835686-C95520B5-4C3C-46A5-95AA-BC5701DF5DB7
P2860
Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Atherosclerosis in early rheum ...... ion of intima media thickness.
@ast
Atherosclerosis in early rheum ...... ion of intima media thickness.
@en
Atherosclerosis in early rheum ...... ion of intima media thickness.
@nl
type
label
Atherosclerosis in early rheum ...... ion of intima media thickness.
@ast
Atherosclerosis in early rheum ...... ion of intima media thickness.
@en
Atherosclerosis in early rheum ...... ion of intima media thickness.
@nl
prefLabel
Atherosclerosis in early rheum ...... ion of intima media thickness.
@ast
Atherosclerosis in early rheum ...... ion of intima media thickness.
@en
Atherosclerosis in early rheum ...... ion of intima media thickness.
@nl
P2093
P2860
P356
P1476
Atherosclerosis in early rheum ...... ion of intima media thickness.
@en
P2093
Anna Södergren
Catharina Eriksson
Elisabet Lundström
Kjell Karp
Lisbet Söderlund
Solveig Wållberg-Jonsson
Torgny Smedby
P2860
P2888
P356
10.1186/AR3116
P577
2010-08-16T00:00:00Z
P5875
P6179
1035800697